Cefpodoxime proxetil

Edina Avdic, Pharm.D., BCPS, Paul A. Pham, Pharm.D.
Cefpodoxime proxetil is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

NON-FDA APPROVED USES

  • Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
  • Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
    • IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 4, 2018